Advancing Forward: BioRay & Alioth Host Biopharma Enterprise Tour – Chengdu Station!

1. HCPs and HCDs are major process-related impurities that pose potential risks to the quality of biopharmaceutical products, and regulatory authorities have established clear limits for their levels.

2. Currently, the removal of host cell proteins (HCPs) presents significant challenges. Control strategies in the manufacturing process primarily include optimizing upstream process conditions such as cell culture and molecular construct design, as well as employing downstream purification techniques like chromatography and filtration to facilitate HCP clearance.

3. Depth filters consist of cellulose, filter aids, and resins, and they clarify and remove impurities through multiple mechanisms, including direct interception, inertial impaction, diffusional interception, and adsorption. Optimization of depth filtration for the removal of host cell proteins (HCP) and host cell DNA (HCD) can be achieved by selecting appropriate filter types, optimizing filtration process parameters, and improving upstream feedstock production processes, with the aim of achieving highly efficient impurity removal. For example, pre-removing more DNA during the clarification of cell harvest fluid helps enhance the removal of HCP by affinity chromatography.

1. Revvity offers two high-speed analytical technologies—high-speed imaging analysis and microfluidic chip capillary electrophoresis—which have numerous applications in biosafety and bioprocessing, effectively facilitating the development and evaluation of biologics.

2. High-speed imaging analysis technology can be applied in areas such as monoclonality verification, viral clearance validation, cell counting, and viability analysis. Specific products include the Celigo whole-field cell scanning analyzer and the Cellaca MX high-throughput cell counter. Notably, for monoclonality verification, the monoclonality report generated by the Celigo whole-field cell scanning analyzer software can be submitted as supporting documentation for Investigational New Drug (IND) applications.

3. Microfluidic chip capillary electrophoresis technology can be used for efficient protein characterization and detection of residual host cell DNA, among other applications. Specific products include the LabChip® microfluidic system for protein and nucleic acid characterization and analysis, and the JANUS qPCR assay setup workstation.

1. In terms of regulatory compliance, there are differences in the biopharmaceutical regulatory frameworks, related regulations, and guidelines both domestically and internationally, with significant disparities particularly among the regulatory systems in China, the United States, and Europe. These differences will also have a direct impact on clinical trial applications, commercialization applications, and other submissions for candidate products.

2. In the biopharmaceutical manufacturing process, biosafety risks are ubiquitous. Even in highly clean production environments, operators may be the primary source of contamination.

3. Biosafety risks can only be controlled to the best extent possible, but cannot be completely eliminated. Among these measures, biosafety testing is a critical means of risk control. It is particularly important to implement comprehensive control over production processes, biosafety testing, and the entire production cycle in accordance with GMP-grade procedures, through the three risk management steps of risk identification, risk control, and risk review, thereby further ensuring the consistency and reliability of product quality.

1. Companies should pay particular attention to the updated EU GMP Annexes and China’s 2018 Technical Guidelines for Sterilizing Filtration, as many of their provisions and requirements may accelerate corporate progress in hardware and quality system upgrades.

2. Requirements for PUPSIT (Pre-Use Post-Sterilization Integrity Test) vary across different countries and regions. The European Union’s requirements are particularly stringent; even when performing PUPSIT poses operational challenges, regulations generally mandate its execution, while permitting exceptions under special circumstances. In practice, most companies, especially Chinese firms, tend to comply with these requirements to avoid the complexities of regulatory scrutiny. However, when making decisions, users should balance the risks associated with implementing PUPSIT against the potential risk of masking filter defects.

3. Regulations do not mandate redundant filtration; however, in practice, most companies implement redundant filtration as a precautionary measure to mitigate economic risks.

4. Regarding sterilizing-grade filtration validation, frequent re-validation is unnecessary when process conditions remain unchanged. However, any changes, such as those involving the facility, batch size, supplier, or sterilization conditions, require re-evaluation. For instance, when a company expands production leading to a change in filter size, validation must be considered even if the scale-up is proportional. In particular, the increased level of extractables resulting from a larger filter surface area must be assessed to ensure it remains within patient safety thresholds.

1. Currently, regulatory authorities such as the WHO, ICH, EMA, FDA, and NMPA encourage the use of NGS as an alternative to in vitro biological screening assays. For viral vaccines or vectors that cannot be neutralized by antibodies, NGS serves as a suitable alternative method. Furthermore, compliance validation, reference standards, standard databases, analytical method validation, and scope of applicability are currently key focal points in regulatory development.

2. NGS offers advantages such as high sensitivity, high specificity, and broad pathogen detection capability, making it suitable for whole-genome sequencing-based identification of viruses and screening for exogenous viral agents in biosafety testing.

3. The application of NGS technology still has certain limitations. Currently, there is no unified standard for the validation of NGS methods, and further confirmation is needed to ensure their suitability for regulatory environments. In addition, challenges such as large data volumes, diverse virus types, selection of reference viruses, diagnostic criteria, and analytical workflows remain key developmental hurdles to be overcome.